0001104659-23-093913.txt : 20230821
0001104659-23-093913.hdr.sgml : 20230821
20230821160629
ACCESSION NUMBER: 0001104659-23-093913
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230817
FILED AS OF DATE: 20230821
DATE AS OF CHANGE: 20230821
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: McKenna Mark C.
CENTRAL INDEX KEY: 0001749623
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41740
FILM NUMBER: 231189185
MAIL ADDRESS:
STREET 1: 400 SOMERSET CORPORATE BOULEVARD
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Apogee Therapeutics, Inc.
CENTRAL INDEX KEY: 0001974640
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 880588063
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 221 CRESCENT ST.
STREET 2: BUILDING 17, SUITE 102B
CITY: WALTHAM
STATE: MA
ZIP: 02453
BUSINESS PHONE: 650-394-5230
MAIL ADDRESS:
STREET 1: 221 CRESCENT ST.
STREET 2: BUILDING 17, SUITE 102B
CITY: WALTHAM
STATE: MA
ZIP: 02453
FORMER COMPANY:
FORMER CONFORMED NAME: Apogee Therapeutics, LLC
DATE OF NAME CHANGE: 20230420
4
1
tm2324209-2_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2023-08-17
0
0001974640
Apogee Therapeutics, Inc.
APGE
0001749623
McKenna Mark C.
C/O APOGEE THERAPEUTICS, INC.
221 CRESCENT ST., BLDG. 17, STE. 102B
WALTHAM
MA
02453
1
0
0
0
0
Stock Option (Right to Buy)
23.60
2023-08-17
4
A
0
50000
0.00
A
2033-08-17
Common Stock
50000
50000
D
Stock Option (Right to Buy)
23.60
2023-08-17
4
A
0
100000
0.00
A
2033-08-17
Common Stock
100000
150000
D
This option represents the right to purchase 50,000 shares of the Issuer's common stock, which will vest in thirty-six equal monthly installments over a three-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer.
This option represents the right to purchase 100,000 shares of the Issuer's common stock, which will vest in thirty-six equal monthly installments over a three-year period from the date of grant, contingent upon approval of the option at the Issuer's 2024 Annual Meeting of Stockholders and subject to the Reporting Person's continued service to the Issuer.
/s/ Matthew Batters, as attorney-in-fact for Mark McKenna
2023-08-21